http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 23 Oct 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/GeneDx+to+Report+Third+Quarter+2026+Financial+Results+on+Monday%2C+November+9%2C+2026/27227846.html <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. </p><p> Conference Call Details </p><p> Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx http://www.streetinsider.com/Press+Releases/GeneDx+to+Report+Third+Quarter+2026+Financial+Results+on+Monday%2C+November+9%2C+2026/27227846.html Fri, 23 Oct 2026 16:05:00 -0400 WGS http://www.streetinsider.com/Business+Wire/GeneDx+to+Report+Third+Quarter+2026+Financial+Results+on+Monday%2C+November+9%2C+2026/27227846.html <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. </p><p> Conference Call Details </p><p> Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx http://www.streetinsider.com/Business+Wire/GeneDx+to+Report+Third+Quarter+2026+Financial+Results+on+Monday%2C+November+9%2C+2026/27227846.html Fri, 23 Oct 2026 16:05:00 -0400 WGS http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27210420.html <p>GeneDx (Nasdaq: WGS) announced plans to add long-read whole genome sequencing (lrWGS) to its genome testing portfolio, with an early access program expected to be available by year-end, according to a company statement.</p> <p>Long-read sequencing analyzes longer stretches of DNA than traditional short-read sequencing, allowing it to identify certain structural variants and repeat expansions that standard methods may miss. GeneDx said it will use a phenotype-driven approach to identify eligible patients for upfront lrWGS testing, with the aim of reducing sequential testing and accelerating diagnosis in rare disease cases.</p> <p>The company said the offering will combine long-read sequencing data with its GeneDx http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27210420.html Tue, 20 Oct 2026 16:05:22 -0400 WGS http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27207221.html <p>GeneDx (Nasdaq: WGS) announced plans to add long-read whole genome sequencing (lrWGS) to its genome testing portfolio, with an early access program expected to be available by year-end, according to a company press release.</p> <p>Long-read sequencing analyzes longer stretches of DNA than traditional short-read sequencing, allowing for the detection of certain structural variants and repeat expansions that standard methods may miss. GeneDx said it will use a phenotype-driven approach to identify patients for whom lrWGS would provide the greatest diagnostic value, with the aim of reducing sequential testing and accelerating rare disease diagnosis.</p> <p>The company said it plans to leverage its GeneDx http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27207221.html Tue, 20 Oct 2026 08:30:23 -0400 WGS WSG http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27207221.html <p>GeneDx (Nasdaq: WGS) announced plans to add long-read whole genome sequencing (lrWGS) to its genome testing portfolio, with an early access program expected to be available by year-end, according to a company press release.</p> <p>Long-read sequencing analyzes longer stretches of DNA than traditional short-read sequencing, allowing for the detection of certain structural variants and repeat expansions that standard methods may miss. GeneDx said it will use a phenotype-driven approach to identify patients for whom lrWGS would provide the greatest diagnostic value, with the aim of reducing sequential testing and accelerating rare disease diagnosis.</p> <p>The company said it plans to leverage its GeneDx http://www.streetinsider.com/FDA/GeneDx+plans+early+access+program+for+long-read+genome+sequencing/27207221.html Tue, 20 Oct 2026 08:30:23 -0400 WGS WSG http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27210401.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27210401.html Tue, 20 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27210401.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27210401.html Tue, 20 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html Tue, 20 Oct 2026 08:30:00 -0400 WGS WSG http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html Tue, 20 Oct 2026 08:30:00 -0400 WGS WSG http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Press+Releases/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html Tue, 20 Oct 2026 08:30:00 -0400 WGS WSG http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html <p class="bwalignc"> <i>GeneDx combines clinical expertise with a phenotype-driven approach to solve complex genetic cases and deliver answers sooner</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). </p><p> Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published research1 and collaborations with leading technology partners, GeneDx is uniquely positioned to bring long-read http://www.streetinsider.com/Business+Wire/GeneDx+Expands+Diagnostic+Leadership+with+Long-Read+Genome+Sequencing%2C+Advancing+Rare+Disease+Diagnosis/27207195.html Tue, 20 Oct 2026 08:30:00 -0400 WGS WSG http://www.streetinsider.com/Press+Releases/GeneDx+Advances+Clinical+Adoption+of+Genomic+Medicine+with+27+Abstracts+at+ASHG+2026/27203828.html <p class="bwalignc"> <i>Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. </p><p> <b>GeneDx research at ASHG 2026 highlights five areas:</b> </p><ul class="bwlistdisc"> <li> <b>Scaling genomic interpretation with AI and machine learning:</b> A GeneDx-led platform presentation explores machine learning to prioritize http://www.streetinsider.com/Press+Releases/GeneDx+Advances+Clinical+Adoption+of+Genomic+Medicine+with+27+Abstracts+at+ASHG+2026/27203828.html Mon, 19 Oct 2026 16:05:00 -0400 WGS http://www.streetinsider.com/Business+Wire/GeneDx+Advances+Clinical+Adoption+of+Genomic+Medicine+with+27+Abstracts+at+ASHG+2026/27203828.html <p class="bwalignc"> <i>Research strengthens the evidence for exome and genome sequencing as standard of care across rare disease, autism, newborn screening and beyond</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. </p><p> <b>GeneDx research at ASHG 2026 highlights five areas:</b> </p><ul class="bwlistdisc"> <li> <b>Scaling genomic interpretation with AI and machine learning:</b> A GeneDx-led platform presentation explores machine learning to prioritize http://www.streetinsider.com/Business+Wire/GeneDx+Advances+Clinical+Adoption+of+Genomic+Medicine+with+27+Abstracts+at+ASHG+2026/27203828.html Mon, 19 Oct 2026 16:05:00 -0400 WGS http://www.streetinsider.com/Press+Releases/GeneDx+Presents+New+Evidence+Advancing+Genomic+Newborn+Screening+at+ICoNS+2026/27158477.html <p class="bwalignc"> <i>New GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families</i> </p><p class="bwalignc"> <i>Data from BRIDGES-NBS shows an expert-informed approach to broadening the number of actionable conditions appropriate for gNBS</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iconseq.org%2Ficons-26&amp;esheet=54617480&amp;newsitemid=20261007662968&amp;lan=en-US&amp;anchor=International+Consortium+on+Newborn+Sequencing+%28ICoNS%29%2C&amp;index=1&amp;md5=f4973517837cbc5b346fa1351eef8f51" shape="rect">International Consortium on Newborn Sequencing (ICoNS),</a> October 7-8 in Boston, demonstrating progress toward making genomic newborn screening (gNBS) a scalable and accessible part of proactive healthcare. </p><p> As http://www.streetinsider.com/Press+Releases/GeneDx+Presents+New+Evidence+Advancing+Genomic+Newborn+Screening+at+ICoNS+2026/27158477.html Wed, 07 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Business+Wire/GeneDx+Presents+New+Evidence+Advancing+Genomic+Newborn+Screening+at+ICoNS+2026/27158477.html <p class="bwalignc"> <i>New GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families</i> </p><p class="bwalignc"> <i>Data from BRIDGES-NBS shows an expert-informed approach to broadening the number of actionable conditions appropriate for gNBS</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new findings to be presented at the <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.iconseq.org%2Ficons-26&amp;esheet=54617480&amp;newsitemid=20261007662968&amp;lan=en-US&amp;anchor=International+Consortium+on+Newborn+Sequencing+%28ICoNS%29%2C&amp;index=1&amp;md5=f4973517837cbc5b346fa1351eef8f51" shape="rect">International Consortium on Newborn Sequencing (ICoNS),</a> October 7-8 in Boston, demonstrating progress toward making genomic newborn screening (gNBS) a scalable and accessible part of proactive healthcare. </p><p> As http://www.streetinsider.com/Business+Wire/GeneDx+Presents+New+Evidence+Advancing+Genomic+Newborn+Screening+at+ICoNS+2026/27158477.html Wed, 07 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Press+Releases/GeneDx+Introduces+Easy+Order+at+AAP+2026+to+Simplify+Genomic+Testing+in+Everyday+Pediatric+Care/27139155.html <p class="bwalignc"> <i>New tools make genomic testing easier from ordering through results, helping pediatricians confidently integrate genomics into routine care</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will introduce Easy Order at the 2026 American Academy of Pediatrics (AAP) National Conference &amp; Exhibition, October 2-6 in San Diego. The new streamlined experience makes it faster and simpler for general pediatricians to order ExomeDx™ and chromosomal microarray (CMA) and is part of GeneDx’s broader effort to simplify genomic testing from ordering through understanding and communicating http://www.streetinsider.com/Press+Releases/GeneDx+Introduces+Easy+Order+at+AAP+2026+to+Simplify+Genomic+Testing+in+Everyday+Pediatric+Care/27139155.html Fri, 02 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Business+Wire/GeneDx+Introduces+Easy+Order+at+AAP+2026+to+Simplify+Genomic+Testing+in+Everyday+Pediatric+Care/27139155.html <p class="bwalignc"> <i>New tools make genomic testing easier from ordering through results, helping pediatricians confidently integrate genomics into routine care</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will introduce Easy Order at the 2026 American Academy of Pediatrics (AAP) National Conference &amp; Exhibition, October 2-6 in San Diego. The new streamlined experience makes it faster and simpler for general pediatricians to order ExomeDx™ and chromosomal microarray (CMA) and is part of GeneDx’s broader effort to simplify genomic testing from ordering through understanding and communicating http://www.streetinsider.com/Business+Wire/GeneDx+Introduces+Easy+Order+at+AAP+2026+to+Simplify+Genomic+Testing+in+Everyday+Pediatric+Care/27139155.html Fri, 02 Oct 2026 08:30:00 -0400 WGS http://www.streetinsider.com/Analyst+PT+Change/GeneDx+%28WGS%29+PT+Raised+to+%2483+at+Guggenheim/27132290.html Guggenheim analyst Subbu Nambi raised the price target on GeneDx (NASDAQ: WGS) to $83.00 (from $74.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/GeneDx+%28WGS%29+PT+Raised+to+%2483+at+Guggenheim/27132290.html Thu, 01 Oct 2026 08:48:39 -0400 WGS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+16++Filed+by%3A+Stueland+Katherine/27081061.html si-local-file:///var/storage/secattach/20260918/27081061.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+16++Filed+by%3A+Stueland+Katherine/27081061.html Fri, 18 Sep 2026 16:43:00 -0400 WGS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+16++Filed+by%3A+Feeley+Kevin/27081028.html si-local-file:///var/storage/secattach/20260918/27081028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+16++Filed+by%3A+Feeley+Kevin/27081028.html Fri, 18 Sep 2026 16:39:00 -0400 WGS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+17++Filed+by%3A+Fuchs+Thomas/27080977.html si-local-file:///var/storage/secattach/20260918/27080977.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+17++Filed+by%3A+Fuchs+Thomas/27080977.html Fri, 18 Sep 2026 16:37:00 -0400 WGS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+09++Filed+by%3A+Stueland+Katherine/27053027.html si-local-file:///var/storage/secattach/20260911/27053027.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+09++Filed+by%3A+Stueland+Katherine/27053027.html Fri, 11 Sep 2026 16:14:00 -0400 WGS http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+09++Filed+by%3A+Feeley+Kevin/27052996.html si-local-file:///var/storage/secattach/20260911/27052996.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GeneDx+Holdings+Corp.+++++For%3A+Sep+09++Filed+by%3A+Feeley+Kevin/27052996.html Fri, 11 Sep 2026 16:11:00 -0400 WGS http://www.streetinsider.com/Corporate+News/Study+finds+rapid+genome+sequencing+boosts+pediatric+diagnoses+at+Seattle+Children%27s/26964678.html <p>GeneDx (Nasdaq: WGS) has announced findings from a study published in <em>Genetics in Medicine</em> showing that hospital-wide implementation of rapid genome sequencing (rGS) across inpatient pediatric care units improved diagnostic rates at Seattle Children's hospital.</p><p>The study, conducted in collaboration with the clinical genetics team at Seattle Children's, evaluated more than 1,000 pediatric inpatients who received rGS across the neonatal intensive care unit, pediatric intensive care unit, cardiac intensive care unit, and non-critical care inpatient wards over a 3.5-year period.</p><p>Key findings included a 35% overall diagnostic yield, with non-ICU inpatient wards recording the highest rate at 43%. Children evaluated for faltering http://www.streetinsider.com/Corporate+News/Study+finds+rapid+genome+sequencing+boosts+pediatric+diagnoses+at+Seattle+Children%27s/26964678.html Mon, 24 Aug 2026 08:34:30 -0400 WGS http://www.streetinsider.com/Press+Releases/GeneDx+Announces+Transformative+Study+Supporting+Hospital-Wide+Adoption+of+Rapid+Genomic+Sequencing+at+Seattle+Children%E2%80%99s/26964607.html <p class="bwalignc"> <i>Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis</i> </p><p class="bwalignc"> <i>Children experiencing faltering growth saw striking 63% diagnostic yield</i> </p> <p> GAITHERSBURG, Md.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genedx.com%2F%3Futm_source%3Dchatgpt.com&amp;esheet=54593153&amp;newsitemid=20260824639564&amp;lan=en-US&amp;anchor=GeneDx&amp;index=1&amp;md5=c8cddb5dabad59ce705eae14432ff816" shape="rect">GeneDx</a> (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data published in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gimjournal.org%2Farticle%2FS1098-3600%252826%252901003-8%2Ffulltext&amp;esheet=54593153&amp;newsitemid=20260824639564&amp;lan=en-US&amp;anchor=Genetics+in+Medicine&amp;index=2&amp;md5=88e15f87482d469395b9fcc7e30b031c" shape="rect">Genetics in Medicine</a>, an official journal of the American College of Medical Genetics and Genomics (ACMG), in collaboration with the clinical genetics team at Seattle Children’s. The study demonstrates that http://www.streetinsider.com/Press+Releases/GeneDx+Announces+Transformative+Study+Supporting+Hospital-Wide+Adoption+of+Rapid+Genomic+Sequencing+at+Seattle+Children%E2%80%99s/26964607.html Mon, 24 Aug 2026 08:30:00 -0400 A.00882093 O.00861874 O.02783319 O.48319473 WGS